Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Zamboni

Showing results (121-130 of 180) with videos related to

Pageof 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Pharmacodynamic model of topotecan-induced time course of neutropeniaW C Zamboni, D Z D'Argenio, C F Stewart, et al.
Investigational New Drugs|February 5, 2008
Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID miceWilliam C Zamboni, Laura L Jung, Sandra Strychor, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 13, 2025
Biodegradable nanofibrous scaffolds enhance standard of care for glioblastoma via localized targeted therapyRyan N Woodring, Elizabeth G Graham-Gurysh, Sophie E Mendell, et al.
Cancer Investigation|October 6, 2005
A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancerHeidi H Gillenwater, Jeannine S McCune, Celeste Lindley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft modelsW C Zamboni, C F Stewart, P J Cheshire, et al.
Biomaterials|August 1, 2013
Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacyKevin S Chu, Allison N Schorzman, Mathew C Finniss, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 8, 2018
A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouseM D McSweeney, T Wessler, L S L Price, et al.
Cancer Chemotherapy and Pharmacology|August 24, 2004
Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumorsLaura L Jung, Ramesh K Ramanathan, Merrill J Egorin, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretionW C Zamboni, P J Houghton, R K Johnson, et al.
Clinical Pharmacology and Therapeutics|August 14, 2009
Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignanciesW C Zamboni, S Strychor, L Maruca, et al.
Pageof 18

Showing results (121-130 of 180) with videos related to

Sort By:
Pageof 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Pharmacodynamic model of topotecan-induced time course of neutropeniaW C Zamboni, D Z D'Argenio, C F Stewart, et al.
Investigational New Drugs|February 5, 2008
Plasma and tissue disposition of non-liposomal DB-67 and liposomal DB-67 in C.B-17 SCID miceWilliam C Zamboni, Laura L Jung, Sandra Strychor, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 13, 2025
Biodegradable nanofibrous scaffolds enhance standard of care for glioblastoma via localized targeted therapyRyan N Woodring, Elizabeth G Graham-Gurysh, Sophie E Mendell, et al.
Cancer Investigation|October 6, 2005
A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancerHeidi H Gillenwater, Jeannine S McCune, Celeste Lindley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 1998
Studies of the efficacy and pharmacology of irinotecan against human colon tumor xenograft modelsW C Zamboni, C F Stewart, P J Cheshire, et al.
Biomaterials|August 1, 2013
Nanoparticle drug loading as a design parameter to improve docetaxel pharmacokinetics and efficacyKevin S Chu, Allison N Schorzman, Mathew C Finniss, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 8, 2018
A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouseM D McSweeney, T Wessler, L S L Price, et al.
Cancer Chemotherapy and Pharmacology|August 24, 2004
Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumorsLaura L Jung, Ramesh K Ramanathan, Merrill J Egorin, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 22, 1998
Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretionW C Zamboni, P J Houghton, R K Johnson, et al.
Clinical Pharmacology and Therapeutics|August 14, 2009
Pharmacokinetic study of pegylated liposomal CKD-602 (S-CKD602) in patients with advanced malignanciesW C Zamboni, S Strychor, L Maruca, et al.
Pageof 18